Literature DB >> 30312816

Multidrug-Resistant Acinetobacter baumannii Ventriculostomy-Related Infection, Treated by a Colistin, Tigecycline, and Intraventricular Fibrinolysis.

François Perier1, Severine Couffin2, Mathieu Martin2, Jean Bardon2, Fabrice Cook2, Roman Mounier2.   

Abstract

BACKGROUND: Acinetobacter baumannii meningitis and ventriculitis are difficult issues, because of the low diffusion of antibiotics in the cerebrospinal fluid and bacterial multidrug resistance. The presence of an infected intraventricular hematoma, constituting an equivalent of undrained abscess, may promote biofilm formation and failure of medical treatment. CASE DESCRIPTION: In this case of ventriculostomy-related infection after ventricular hemorrhage, Acinetobacter baumannii was sensitive only to colistin and tigecycline. Despite a combination therapy involving intraventricular injections of colistin, we observed clinical and bacteriologic failure. Therefore, at day 4 of antibiotic therapy, we performed intraventricular fibrinolysis, which dissolved the clot, enabling sterilization of the cerebrospinal fluid after 48 hours.
CONCLUSION: This clinical case suggests the usefulness of intraventricular fibrinolysis to lyse the clot and optimize the action of antibiotics.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Acinetobacter baumannii; Intraventricular fibrinolysis; Ventriculostomy-related infection

Mesh:

Substances:

Year:  2018        PMID: 30312816     DOI: 10.1016/j.wneu.2018.09.218

Source DB:  PubMed          Journal:  World Neurosurg        ISSN: 1878-8750            Impact factor:   2.104


  2 in total

1.  A Systematic Review of Studies Reporting Antibiotic Pharmacokinetic Data in the Cerebrospinal Fluid of Critically Ill Patients with Uninflamed Meninges.

Authors:  Nilesh Kumta; Jason A Roberts; Jeffrey Lipman; Wai Tat Wong; Gavin M Joynt; Menino Osbert Cotta
Journal:  Antimicrob Agents Chemother       Date:  2020-12-16       Impact factor: 5.191

Review 2.  Intrathecal Antibacterial and Antifungal Therapies.

Authors:  Roland Nau; Claudia Blei; Helmut Eiffert
Journal:  Clin Microbiol Rev       Date:  2020-04-29       Impact factor: 26.132

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.